Design and synthesis of novel 2-phenylaminopyrimidine (PAP) derivatives and their antiproliferative effects in human chronic myeloid leukemia cells

Molecules

Volumn 14, Issue 10, 2009, Pages 4166-4179

  Chang, Sheng ^a   Yin, Shi Liang ^a   Wang, Jian ^a   Jing, Yong Kui ^b   Dong, Jin Hua ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

2 Phenylaminopyrimidine (PAP) derivative; Antiproliferative activity; STI 571

Indexed keywords

(E) 3 (2 BROMOPHENYL) N (4 METHYL 3 (4 PYRIDIN 3 YL PYRIMIDIN 2 YLAMINO)PHENYL)ACRYLAMIDE; (E)-3-(2-BROMOPHENYL)-N-(4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)PHENYL)ACRYLAMIDE; ACRYLAMIDE DERIVATIVE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ARTICLE; CELL PROLIFERATION; CHEMISTRY; CHRONIC MYELOID LEUKEMIA; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; SYNTHESIS; TUMOR CELL LINE;

ACRYLAMIDES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 70350506062     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules14104166     Document Type: Article

References (22)

1. Warmuth, M.; Danhauser-Riedl, S.; Hallek, M. Molecular patho-genesis of chronic myeloid leukemia: Implications for new therapeutic strategies. Ann. Hematol. 1999, 78, 49-64.
2. Gishizky, M.L. Molecular mechanisms of Bcr-Abl-induced oncogenesis. Cytokines Mol. Ther. 1996, 2, 251-261.
3. Cortes, J.E.; Talpaz, M.; KantarJian, H. Chronic myelogenous leukemia: A review. Am. J. Med. 1996, 100, 555-570.
4. Nowell, P.C.; Hungerford, D.A. A minute chromosome in human chronic granulocytic leukemia. Science 1960, 132, 1497-1501.
5. Rowley, J.D. A new consistent chromosmal abnormality in chronic myelgenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243, 290-293.
6. Wong, S.; Witte, O.N. The BCR-ABL story: Bench to beside and back. Annu. Rev. Immunol. 2004, 22, 247-306.
7. Druker, B.J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G.M.; Fanning, S.; Zimmermann, J.; Lydon, N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 1996, 2, 561-566.
8. Druker, B.J.; Talpaz, M.; Resta, D.J.; Peng, B.; Buchdunger, E.; Ford, J.M.; Lydon, N.B.; Kantariian, H.; Capedeville, R.; Ohno-Jones, S.; Sawyer, C.L. Efficacy and safety of a specific inhibitor of Bcr-Abl tyrosine kinase in chronicmyeloid leukemia. N. Eng. J. Med. 2001, 344, 1031-1037.
9. Roche-Lestienne, C.; Soenen-Cornu, V.; Grardel-Duflos, N.; Laï, J.L.; Philippe, N.; Facon, T.; Fenaux, P.; Preudhomme, C. Several types of mutations of the Abl can be found in chronic meloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002, 100, 1014-1018.
10. Hochhaus, A.; Kreil, S.; Corbin, A.S.; La Rosée, P.; Muller, M.C.; Lahaye, T.; Hanfstein, B.; Schoch, C.; Cross, N.C.U.; Berger, U.; Gschaidmeier, H.; Druker, B.J.; Hehlmann, R. Molecular and chromosomal mechanisms of resistance to imanitib (STI-571) therapy. Leukemia 2002, 11, 2190-2196.
11. Gorre, M.E.; Mohammed, M.; Ellwood, K.; Hsu, N.; Paquette, R.; Rao, P.N.; Sawyers, C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293, 876-880.
12. Nagar, B.; Bornmann, W.G.; Pellicena, P.; Schindler, T.; Veach, D.R.; Miller, W.T.; Clarkson.; Kuriyan, J. Cystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitor PD173955 and imatinib(STI-571). Cancer Res. 2002, 62, 4236-4243.
13. Schindler, T.; Bornmann, W.; Pellicena, P.; Miller, W.T.; Clarkson, B.; Kuriyan, J. Structure Mechanism for STI-571 inhibition of Ableson Tyrosine kinase. Science 2000, 289, 1938-1942.
14. Zimmermann, J.; Buchdunger, E.; Mett, H.; Meyer, T.; Lydon, N.B.; Potent and selective inhibitors of the Abl-kinase: Phenylaminopyrimidine (PAP) derivatives. Bioorg. Med. Chem. Lett. 1997, 7, 187-192.
15. Rachid, Z.; Katsoulas, A.; Brahimi, F.; Jean-Claude, B.J. Synthesis of pyrimidinopyridine-triazene conjugates targeted to Abl tyrosine kinase. Bioorg. Med. Chem. Lett. 2003, 13, 3297-3300.
16. Manley, P.W.; Breitenstein, W.; Bruggen, J.; Cowan-Jacob, S.W.; Furet, P.; Mesta, J.; Meyer, T.; Urea derivatives of STI-571 as inhibitors of Bcr-Abl and PDGFR kinases. Bioorg. Med. Chem. Lett. 2004, 14, 5793-5797.
17. Asaki, T.; Sugiyama, Y.; Hamamoto, T.; Higashioka, M.; Umehara, M.; Naito, H.; Niwa, T. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 1421-1425.
18. O'Hare, M.; Walters, D.K.; Deiniger, M.W.N.; Druker, B.J. AMN 107: Tightening the grip of imatinib. Cancer Cell. 2005, 7, 117-119.
19. Bredereck, H.; Effenberger, F.; Bosch, H. Ber. Dtsch. Chem. Ges. 1964, 97, 3397-3406.
20. Belhacene, N.; Maulon, L.; Guerin, S.; Ricci, J. E.; Mari, B.; Colin, Y.; Cartron, J.P.; Auberger, P. Differential expression of the Kell blood group and CD10 antigens: Two related membrane metallopeptidases during differentiation of K562 cells by phorbol ester and hemin. FASEB J. 1998, 12, 531-539.
21. Thomsen, R.; Christensen, M.H. MolDock: A new technique for high-accuracy molecular docking. J. Med. Chem. 2006, 49, 3315-3321.
22. Sybyl Version 6.9.1; Tripos Associates: St. Louis, MO, USA, 2003.